News: Boehringer Ingelheim

09.09.2010 | Business Wire: Exelixis Announces Webcasts of Presentations at Upcoming Investor Conferences | Business Wire

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey, PhD, the company s president and chief executive officer, will present at the following two investor conferences during the month of September 2010: The Stifel (…)

[Read article]

[Source: Business Wire]

02.09.2010 | NCBI PubMed: Room Temperature Palladium-Catalyzed Cross Coupling of Aryltrimethylammonium Triflates with Aryl Grignard Reagents.

Aryltrimethylammonium triflates and tetrafluoroborates were found to be highly reactive electrophiles in the Pd-catalyzed cross coupling with aryl Grignard reagents. The coupling reactions proceed at ambient temperature with a nearly stoichiometric quantity of Grignard reagent, (…)

[Read article]

[Source: NCBI PubMed]

07.09.2010 | NCBI PubMed: Preclinical Characterization of BI 201335, a C-terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease.

BI 201335 is a HCV NS3-NS4A protease inhibitor that has been shown to have potent clinical antiviral activity. It is a highly optimized non-covalent competitive inhibitor of full-length NS3-NS4A proteases of genotypes 1a and 1b with Ki values of 2.6 and 2.0 nM, respectively. Ki (…)

[Read article]

[Source: NCBI PubMed]

01.09.2010 | NCBI PubMed: Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.

OBJECTIVE: The aim of this meta-analysis was to compare the 24-h antihypertensive efficacy of different treatments using the smoothness index. METHODS: Data were taken from the telmisartan ambulatory blood pressure monitoring (ABPM) clinical programme. Eleven clinical trials (…)

[Read article]

[Source: NCBI PubMed]

01.09.2010 | NCBI PubMed: The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) in vitro system: Design and experimental protocol.

The development of aerosol medicines typically involves numerous tests on animals, due to the lack of adequate in vitro models. A new in vitro method for testing pharmaceutical aerosol formulations on cell cultures was developed, consisting of an aerosolisation unit fitting a (…)

[Read article]

[Source: NCBI PubMed]

03.09.2010 | NCBI PubMed: Palladium-Catalyzed Cross-Coupling of Cyclopropylmagnesium Bromide with Aryl Bromides Mediated by Zinc Halide Additives.

The key Pd-catalyzed cross-coupling of aryl bromides or triflates and cyclopropylmagnesium bromide in the presence of substoichiometric amounts of zinc bromide produces cyclopropyl arenes in good to excellent yields. The cross-coupling of other alkyl, cycloalkyl, and aryl (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective.

l-DOPA-induced dyskinesia is a debilitating, treatment-limiting adverse effect that eventually occurs in the majority of Parkinson's disease patients. This review describes the strategy of biological testing, focusing on in vivo proof-of-concept animal models. We distinguish (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

BACKGROUND: Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2.0-3.0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced (…)

[Read article]

[Source: NCBI PubMed]

06.09.2010 | Medical News Today: Research By DNA Fingerprinting Pioneer And His Team At University Of Leicester Defines Engine For Change In Genetic Hotspots

One of the key drivers of human evolution and diversity, accounting for changes that occur between different generations of people, is explained by new research published by world-renowned scientist Professor Sir Alec Jeffreys, who discovered DNA fingerprinting at the (…)

[Read article]

[Source: Medical News Today]

06.09.2010 | Business Wire: Research and Markets: Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6e510d/manufacturing_of_b) has announced the addition of the "Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in (…)

[Read article]

[Source: Business Wire]

05.09.2010 | ScienceDaily: Role of Key Genetic Catalyst for Human Diversity Discovered

ScienceDaily (Sep. 5, 2010) One of the key drivers of human evolution and diversity, accounting for changes that occur between different generations of people, is explained by new research published by Professor Sir Alec Jeffreys, who discovered DNA fingerprinting at the (…)

[Read article]

[Source: ScienceDaily]

03.09.2010 | Business Wire: Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Business Wire

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the (…)

[Read article]

[Source: Business Wire]

03.09.2010 | Bionity.com: Evotec Completes Acquisition of DeveloGen

03.09.2010 - Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the (…)

[Read article]

[Source: Bionity.com]

02.09.2010 | BioSpace: Boehringer Ingelheim Corporation Opens ˜Centre Of Competence Opens As Part Of A ¬100m China Plan

Oustourcing Pharma - Boehringer Ingelheim has opened its ˜Centre of Competence (CoC) in Shanghai to optimise API and chemical intermediates sourcing in China.

[Read article]

[Source: BioSpace]

01.09.2010 | Medical News Today: Combination Therapy Of Telmisartan And Amlodipine Provides Significantly Better Blood Pressure Lowering Than Either Agent Alone

Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.1 The data, which was (…)

[Read article]

[Source: Medical News Today]

01.09.2010 | Business Wire: Research and Markets: Argentina Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

01.09.2010 | Business Wire: AHF Offers Solution to End Florida s AIDS Drug Waiting List | Business Wire

FT LAUDERDALE, Fla.-(BUSINESS WIRE)-As the State of Florida grapples with a budget shortfall that is crippling its AIDS Drug Assistance Program (ADAP) and forcing the state to place more than 1,300 low-income Floridians on waiting lists to access lifesaving AIDS medications, (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Medical News Today: New Global Campaign Aims To Prevent As Many As 1 Million Atrial Fibrillation-Related Strokes

1 Mission 1 Million - Getting to the Heart of Stroke launches announcing a worldwide effort to help prevent as many as 1 million atrial fibrillation (AF)-related strokes through increased awareness and understanding. This first-of-its kind initiative calls for the submission of (…)

[Read article]

[Source: Medical News Today]

30.08.2010 | Business Wire: A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront | Business Wire

INGELHEIM, Germany-(BUSINESS WIRE)-The European Society of Cardiology (ESC) today issued revised practice guidelines for the management of atrial fibrillation (AF), including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | BioSpace: Boehringer Ingelheim Corporation Release: Sub-Analysis Shows Primary Benefits seen with RE-LY(R) are Independent of Level of Centre-Based International Normalized Ratio Control

INGELHEIM, Germany-(BUSINESS WIRE)-Boehringer Ingelheim today announced that results from a pre-specified sub-group analysis of the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy, Warfarin, Compared with Dabigatran) the largest atrial fibrillation (…)

[Read article]

[Source: BioSpace]

29.08.2010 | Business Wire: New Global Campaign Aims to Prevent as Many as 1 Million Atrial Fibrillation-Related Strokes | Business Wire

STOCKHOLM-(BUSINESS WIRE)-1 Mission 1 Million Getting to the Heart of Stroke launches today announcing a worldwide effort to help prevent as many as 1 million atrial fibrillation (AF)-related strokes through increased awareness and understanding. This first-of-its kind (…)

[Read article]

[Source: Business Wire]

29.08.2010 | Business Wire: Sub-Analysis Shows Primary Benefits seen with RE-LY are Independent of Level of Centre-Based International Normalized Ratio Control | Business Wire

INGELHEIM, Germany-(BUSINESS WIRE)-Boehringer Ingelheim today announced that results from a pre-specified sub-group analysis of the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy, Warfarin, Compared with Dabigatran) the largest atrial fibrillation (…)

[Read article]

[Source: Business Wire]

27.08.2010 | Medical News Today: American Lung Association Joins Lung Cancer Clinical Trial Call To Action Campaign

The American Lung Association is encouraging patients with lung cancer to take charge of their diagnosis and learn about clinical trials through the Lung Cancer Clinical Trial Call to Action campaign. This service provides personalized education to quickly identify trial (…)

[Read article]

[Source: Medical News Today]

26.08.2010 | Business Wire: Research and Markets: Fixed Dose Combination Products - Identify the Proven Strategies for Developing & Commercializing FDC Products | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/614240/fixed_dose_combina) has announced the addition of the "Fixed Dose Combination Products" report to their offering. Fixed dose combination (FDC) products are becoming increasingly (…)

[Read article]

[Source: Business Wire]

24.08.2010 | NCBI PubMed: Nonsteroidal Dissociated Glucocorticoid Agonists Containing Azaindoles as Steroid A-Ring Mimetics.

Syntheses and structure-activity relationships (SAR) of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain azaindole moieties as A-ring mimetics and display various degrees of in vitro dissociation between gene transrepression and (…)

[Read article]

[Source: NCBI PubMed]

26.08.2010 | BioSpace: FDA Panel To Vet Boehringer Ingelheim Corporation Blood Thinner September 20

FRANKFURT, Aug 26 (Reuters) - A committee advising the U.S. Food and Drug Administration (FDA) will discuss Boehringer Ingelheim's Pradaxa pill on Sept. 20, raising the prospect of a speedy market entry for the first drug in a new class of blood thinners.

[Read article]

[Source: BioSpace]

25.08.2010 | Medical News Today: AMGA Announces Learning Collaborative, Managing Chronic Obstructive Pulmonary Disease (COPD)

The American Medical Group Association (AMGA) and the American Medical Group Foundation (AMGF) are pleased to announce an opportunity for AMGA members to participate in a learning collaborative on care management for patients with COPD. The Best Practices Learning Collaborative (…)

[Read article]

[Source: Medical News Today]

25.08.2010 | Business Wire: Research and Markets: Educating the Market: Creating Value Through Support of Continuing Medical Education 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Maven Semantic: Database of German Life Sciences Research Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their German healthcare research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Maven Semantic: Biomarker Research Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Biomarker research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Research and Markets: Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/81e154/raising_disease_st) has announced the addition of the "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products" report to their offering. (…)

[Read article]

[Source: Business Wire]

25.08.2010 | BioSpace: Ablynx Announces Half Year Results For 2010

GHENT, BELGIUM-(Marketwire - August 25, 2010) - GHENT, Belgium, 25 August 2010 - Ablynx [Euronext Brussels: ABLX] announced today its results for the six month period ending 30 June 2010, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as (…)

[Read article]

[Source: BioSpace]

23.08.2010 | Marketwire: Larry Kranking Named CEO of Coldstream Laboratories Inc.

Highlighted Links Coldstream Laboratories Inc. LEXINGTON, KY-(Marketwire - August 23, 2010) - Larry Kranking has been named the new President and CEO of Coldstream Laboratories Inc. (CLI), the largest sterile pharmaceutical manufacturing facility in Kentucky. Kranking, who (…)

[Read article]

[Source: Marketwire]

24.08.2010 | Business Wire: Maven Semantic: The Largest Database of International Osteoarthritis Research Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Osteoarthritis research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned (…)

[Read article]

[Source: Business Wire]

24.08.2010 | BioSpace: Larry Kranking Named CEO of Coldstream Laboratories Inc.

LEXINGTON, KY-(Marketwire - August 23, 2010) - Highlighted Links Coldstream Laboratories Inc. Larry Kranking has been named the new President and CEO of Coldstream Laboratories Inc. (CLI), the largest sterile pharmaceutical manufacturing facility in Kentucky. Kranking, who (…)

[Read article]

[Source: BioSpace]

17.08.2010 | NCBI PubMed: Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335).

C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these linear inhibitors (…)

[Read article]

[Source: NCBI PubMed]

18.08.2010 | Business Wire: Research and Markets: Biomarkers: Discovery Techniques and Applications - a Global Market Overview | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bd425b/biomarkers_discov) has announced the addition of the "Biomarkers: Discovery Techniques and Applications A Global Market Overview" report to their offering. Biomarkers: Discovery (…)

[Read article]

[Source: Business Wire]

17.08.2010 | Business Wire: Maven Semantic: Database of Bioavailability / Bioequivalence Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Bioavailability / Bioequivalence database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not (…)

[Read article]

[Source: Business Wire]

17.08.2010 | Business Wire: Research and Markets: The Cardiovascular Market Outlook to 2015: Competitive Landscape, Global Market Analysis, Key Trends and Pipeline analysis | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/7f25f4/the_cardiovascular) has announced the addition of the "The Cardiovascular Market Outlook to 2015: Competitive Landscape, Global Market Analysis, Key Trends and Pipeline analysis" (…)

[Read article]

[Source: Business Wire]

17.08.2010 | Business Wire: Maven Semantic: Database of Enzyme Linked Immunosorbent Assays (ELISAs) Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their ELISAs research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - for (…)

[Read article]

[Source: Business Wire]

17.08.2010 | Business Wire: Research and Markets: Boehringer Ingelheim GmbH: PharmaVitae Profile | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f48fd7/boehringer_ingelhe) has announced the addition of the "Boehringer Ingelheim GmbH: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]